Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by MustangSalleyon Jan 06, 2022 7:38pm
174 Views
Post# 34291202

RE:RE:RE:RE:RE:RE:New base $2

RE:RE:RE:RE:RE:RE:New base $2

Mouth,

You make a very valid point . Even with a single top up, insulin independence is wuite remarkable . How many patients would go for that ? 

it is a significant milestone in itself.
 

If you look at the recent December presentation , take careful note that they are now manufacturing several sizes of the pouch according to Gmp specs. This is significant because it means they can implant varying sizes of pouches or more than mulch in a patient . This might give Witowski leeway so he can dose the appropriate number of islet cells on the pouch to achieve insulin independence . I believe they are close and there will be no top up . Just my intuition.

The thing that baffles me why they don't have the 7 th patient yet ?  Perhaps Witioeski can answer some of these questions .

Keep up the great dialogue Mouth! Nice conversing on an intellectual level on this blog.

Ms Sally 

<< Previous
Bullboard Posts
Next >>